Insights on the regeneration potential of Müller glia in the mammalian retina by Salman, A, McClements, ME, MacLaren, RE

RNA editing for Usher syndrome using CRISPR-Cas13 by Fry, LE, Barnard, AR, McClements, ME, MacLaren, RE

Minicircle delivery to the neural retina as a gene therapy approach by Staurenghi, F, McClements, ME, Salman, A, MacLaren, RE

RNA editing as a therapeutic approach for retinal gene therapy requiring long coding sequences by Fry, LE, Peddle, CF, Barnard, AR, McClements, ME, MacLaren, RE

In silico analysis of pathogenic CRB1 single nucleotide variants and their amenability to base editing as a potential lead for therapeutic intervention by Bellingrath, J-S, McClements, ME, Kaukonen, M, Fischer, MD, MacLaren, RE

Non-viral delivery of CRIPSR/Cas cargo to the retina using nanoparticles: current possibilities, challenges, and limitations by Salman, A, Kantor, A, McClements, ME, Marfany, G, Trigueros, S, MacLaren, RE

Is subretinal AAV gene replacement still the only viable treatment option for choroideremia? by Han, RC, Fry, LE, Kantor, A, McClements, ME, Xue, K, MacLaren, RE

Cell-mediated inflammatory response to AAV gene therapy in the retina by Chandler, LC, Yusuf, IH, Ferry, H, McClements, ME, MacLaren, RE, Xue, K

Envisioning the development of a CRISPR-Cas mediated base editing strategy for a patient with a novel pathogenic CRB1 single nucleotide variant by Bellingrath, J-S, McClements, ME, Shanks, M, Clouston, P, Fischer, MD, MacLaren, RE

Gene Therapies in Clinical Development to Treat Retinal Disorders by McClements, ME, Elsayed, MEAA, Major, L, de la Camara, CM, MacLaren, RE

Promoter orientation within an AAV-CRISPR vector affects Cas9 expression and gene editing efficiency by Fry, LE, Peddle, CF, Stevanovic, M, Barnard, AR, McClements, ME, MacLaren, RE

Association of a novel intronic variant in RPGR with hypomorphic phenotype of x-linked retinitis pigmentosa by Cehajic-Kapetanovic, J, McClements, ME, Whitfield, J, Shanks, M, Clouston, P, MacLaren, RE

An AAV dual vector strategy ameliorates the Stargardt phenotype in adult Abca4−/− mice by McClements, ME, Barnard, AR, Singh, MS, Issa, P, Jiang, Z, Radu, RA, Maclaren, RE

Mirtron-mediated RNA knockdown/replacement therapy for the treatment of dominant retinitis pigmentosa by Orlans, HO, McClements, ME, Barnard, AR, Martinez-Fernandez de la Camara, C, MacLaren, RE

Genome-editing strategies for treating human retinal degenerations by Quinn, J, Musa, A, Kantor, A, McClements, ME, Cehajic-Kapetanovic, J, MacLaren, RE, Xue, K

Characterizing the cellular immune response to subretinal AAV gene therapy in the murine retina by Chandler, LC, McClements, ME, Yusuf, IH, Martinez-Fernandez de la Camara, C, MacLaren, RE, Xue, K

Tropism of engineered and evolved recombinant AAV serotypes in the rd1 mouse and ex vivo primate retina by Hickey, DG, Edwards, TL, Barnard, AR, Singh, MS, de Silva, SR, McClements, ME, Flannery, JG, Hankins, MW, Maclaren, RE

Codon-optimized RPGR improves stability and efficacy of AAV8 gene therapy in two mouse models of X-linked retinitis pigmentosa by Fischer, MD, McClements, ME, Martinez-Fernandez de la Camara, C, Bellingrath, J-S, Dauletbekov, D, Ramsden, SC, Hickey, DG, Barnard, AR, MacLaren, RE

Single-cell transcriptomic analysis of retinal immune regulation and blood-retinal barrier function during experimental autoimmune uveitis by Quinn, J, Salman, A, Paluch, C, Jackson-Wood, M, McClements, ME, Luo, J, Davis, SJ, Cornall, RJ, MacLaren, RE, Dendrou, CA, Xue, K

Long-term restoration of visual function in end-stage retinal degeneration using subretinal human melanopsin gene therapy by De Silva, SR, Barnard, AR, Hughes, S, Tam, SKE, Martin, C, Singh, MS, Barnea-Cramer, AO, McClements, ME, During, MJ, Peirson, SN, Hankins, MW, MacLaren, RE